Neurosense Therapeutics Ltd. NRSN 深 沪
已收盘 09-04 16:00:00 美东时间
0.5108
+0.109
+27.19%
华盛通- 最 高0.5257
- 今 开0.40
- 成交量 422.41万股
- 最 低 0.36
- 昨 收 0.4016
- 总市值 1929.09万
- 52周最高 1.3319
- 市盈率 静 --
- 换手率 11.18%
- 52周最低 0.25
- 委 比 50.00%
- 总股本 3776.61万
- 历史最高 8.18
- 量 比 32.93
- 振 幅 41.26%
- 历史最低 0.25
- 每 手 1
- 风险率 0.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 大行齐上调AI应用股目标价！Adobe、CRWD等获看好，慧与科技绩后现多空分歧
今日重点评级关注：BTIG：维持Climb Bio"买入"评级，目标价从20美元升至32美元；巴克莱：维持Alpha Tau Medical"超配"评级，目标价从17美元升至30美元
09-04 12:30
NeuroSense Announces Redesigned Development Plan For PrimeC In Amyotrophic Lateral Sclerosis, Structured To Reach Potential Path For Regulatory Submission And Faster Approval
Three-part program - AI-enabled characterization of PrimeC's formulation advantage, an active-comparator trial against edaravone, and a streamlined pivotal pathway - is designed to strengthen PrimeC's differentiation, shorten the time to potential commercialization, and significantly reduce overall ...
08-31 20:48
NeuroSense Issues CEO Letter to Shareholders
CAMBRIDGE, Mass., Aug. 13, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifyin...
08-13 21:30
NeuroSense Intends To Proceed With Filing Of NDS To Health Canada For PrimeC For Treatment Of Amyotrophic Lateral Sclerosis, Following Constructive Pre-NDS Meeting
The planned submission follows alignment with Health Canada on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway biomarker program CAMBRIDGE, Mass., July 22, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd...
07-22 20:38
NeuroSense Posts Positive Phase 2 Biomarker Signals for PrimeC in Alzheimer’s Trial
The latest announcement is out from Neurosense Therapeutics Ltd. ( ($NRSN) ). O...
06-25 21:50
NeuroSense Therapeutics Secures Japanese Patent 7857044 Covering Its Lead Drug Candidate For Treatment Of Amyotrophic Lateral Sclerosis
Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil patentsCAMBRIDGE, Mass., June 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a
06-09 21:06
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition
Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil patents CAMBRIDGE, Mass., June 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroS...
06-09 21:00
NeuroSense Secures Insider-Led $600,000 PIPE at Premium Share Price
Neurosense Therapeutics Ltd. ( ($NRSN) ) has issued an update. On April 28, 202...
04-29 03:57
NeuroSense Announces Pricing of Insider-Led PIPE Financing
Financing led by CEO Alon Ben-Noon and CFO Or Eisenberg, alongside participation from an existing significant shareholder CAMBRIDGE, Mass., April 28, 2026 /PRNewswire/ -- NeuroSense Therapeu...
04-29 02:30
